Skip to main content

EXPONENT INC

For the period ended Oct 3, 2025. Filed Nov 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Oct 3, 2025 · Filed Nov 7, 2025

EXPO$86.00+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1: Basis of Presentation

Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three and nine months ended October 3, 2025 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2025, which was filed with the U.S. Securities and Exchange Commission on February 28, 2025 and amended on April 18, 2025.

The unaudited condensed consolidated financial statements include the accounts of Exponent and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates.

Recent Accounting Pronouncement Not Yet Adopted

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard is effective for annual reporting periods beginning after December 15, 2024. The Company is evaluating the effect that this standard may have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (subtopic 220-40), which requires disclosure of disaggregation of certain relevant expenses included in the statements of operations on an annual and interim basis. ASU 2024-03 will be effective for our annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028. The amendments must be applied retrospectively, and early adoption is permitted. The Company is evaluating the effect that this standard may have on its consolidated financial statements and related disclosures.

Note 2: Revenue Recognition

Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 –Revenue from Contracts with Customers, which states if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided) then the entity may recognize revenue in the amount to which the entity has a right to invoice.

-9 -

The following table discloses the percent of the Company’s revenue generated from time and materials contracts:

Three Months EndedNine Months Ended
October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering & Other Scientific63%63%64%63%
Environmental and Health14%15%15%16%
Total time and materials revenues77%78%79%79%

For fixed-price contracts, the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides.

The following table discloses the percent of the Company’s revenue generated from fixed price contracts:

Three Months EndedNine Months Ended
October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering & Other Scientific22%21%20%20%
Environmental and Health1%1%1%1%
Total fixed price revenues23%22%21%21%

Deferred revenues represent amounts billed to clients in advance of services provided. During the third quarter of 2025, $5,000,000 of revenues were recognized that were included in the deferred revenue balance at July 4, 2025. During the first nine months of 2025, $9,397,000 of revenues were reco gnized that were included in the deferred revenue balance at January 3, 2025.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third- party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange forthe provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $2,578,000 and $2,689,000 during the third quarter of 2025 and 2024, respectively, and $9,259,000 and $9,222,000 during the first nine months of 2025 and 2024, respectively.

-10 -

Note 3: Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including money market securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three and nine months ended October 3, 2025 and September 27, 2024. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at October 3, 2025:

Fair Value Measurements at Reporting Date Using
(In thousands) · Total · Quoted Prices inActive Marketsfor IdenticalAssets (Level 1) · Significant OtherObservable Inputs(Level 2) · SignificantUnobservableInputs(Level 3)
Assets
Money market securities (1)$59,595$59,595$-$-
Fixed income trading securities held in deferred compensation plan (2)44,53344,533--
Equity trading securities held in deferred compensation plan (2)96,15696,156--
Total$200,284$200,284$-$-
Liabilities
Deferred compensation plan (3)142,282142,282--
Total$142,282$142,282$-$-

(1)

Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.

(2)

Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.

(3)

Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

-11 -

The fair value of these certain financial assets and liabilities was determined using the following inputs at January 3, 2025:

Fair Value Measurements at Reporting Date Using
(In thousands) · Total · Quoted Prices inActive Marketsfor IdenticalAssets (Level 1) · Significant OtherObservable Inputs(Level 2) · SignificantUnobservableInputs(Level 3)
Assets
Money market securities (1)$57,549$57,549$-$-
Fixed income trading securities held in deferred compensation plan (2)42,29142,291--
Equity trading securities held in deferred compensation plan (2)85,54685,546--
Total$185,386$185,386$-$-
Liabilities
Deferred compensation plan (3)127,622127,622--
Total$127,622$127,622$-$-

(1)

Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.

(2)

Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.

(3)

Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

Money market securities as of October 3, 2025 and January 3, 2025 represent obligations of the United States Treasury. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 6 for additional information about the Company’s deferred compensation plan.

Cash and cash equivalents consisted of the following as of October 3, 2025:

Gross · Gross
Amortized · Unrealized · Unrealized · Estimated
(In thousands) · Cost · Gains · Losses · Fair Value
Classified as current assets:
Cash$147,785$-$-$147,785
Cash equivalents:
Money market securities59,595--59,595
Total cash equivalents59,595--59,595
Total cash and cash equivalents$207,380$-$-$207,380

-12 -

Cash and cash equivalents consisted of the following as of January 3, 2025:

Amortized · Unrealized · Unrealized · Estimated
(In thousands) · Cost · Gains · Losses · Fair Value
Classified as current assets:
Cash$201,352$-$-$201,352
Cash equivalents:
Money market securities57,549--57,549
Total cash equivalents57,549--57,549
Total cash and cash equivalents$258,901$-$-$258,901

At October 3, 2025 and January 3, 2025, the Company did not have any assets or liabilities valued using significant unobservable inputs.

The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at October 3, 2025 and January 3, 2025, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at October 3, 2025 and January 3, 2025 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheet.

Note 4: Net Income Per Share

Basic per share amounts are computed using the weighted-average number of shares of common stock outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of shares of common stock outstanding during the period and, when dilutive, the weighted-average number of potential shares of common stock from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.

The following schedule reconciles the shares used to calculate basic and diluted net income per share:

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Shares used in basic per share computation50,87251,17751,11351,098
Effect of dilutive common stock options outstanding7117584172
Effect of dilutive restricted stock units outstanding236270257257
Shares used in diluted per share computation51,17951,62251,45451,527

Common stock options to purchase 215,833 and 30,000 shares were excluded from the diluted per share calculation for the three months ended October 3, 2025 and September 27, 2024, respectively, due to their anti-dilutive effect. Common stock options to purchase 175,833 and 63,333 shares were excluded from the diluted per share calculation for the nine months ended October 3, 2025 and September 27, 2024, respectively, due to their anti-dilutive effect.

Note 5: Stock-Based Compensation

Restricted Stock Units

Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company’s common stock for each fully vested restricted stock unit four years fromthe date of grant. Each individual who receives a fully vested restricted stock unit award is also granted

-13 - amatching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company’s common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will continue to vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.

The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of $3,042,000 and $2,842,000 during the three months ended October 3, 2025 and September 27, 2024, respectively. For the nine months ended October 3, 2025 and September 27, 2024, the Company recorded stock-based compensation expense associated with accrued bonus awards of $9,189,000 and $9,238,000, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of thefour-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $2,123,000 and $2,255,000 during the three months ended October 3, 2025 and September 27, 2024, respectively. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $8,438,000 and $8,089,000 during the nine months ended October 3, 2025 and September 27, 2024, respectively.

Stock Options

Stock options are granted for terms often years and generally vest 25% per year over afour-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with stock option grants of $176,000 and $368,000 during the three months ended October 3, 2025 and September 27, 2024, respectively. The Company recorded stock-based compensation expense associated with stock option grants of $1,139,000 and $1,055,000 during the nine months ended October 3, 2025 and September 27, 2024, respectively.

The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.

-14 -

The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights.

The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.

Note 6: Deferred Compensation Plans

The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company’s creditors. As of October 3, 2025 and January 3, 2025, the invested amounts under the plans totaled $140,689,000 and $127,837,000, respectively, and are recorded in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. These assets are classified as trading securities and are recorded at fair value with changes recorded as adjustments to miscellaneous income, net.

As of October 3, 2025 and January 3, 2025, vested amounts due under the plans totaled $142,282,000 and $127,622,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheets. Changes in the liability are recorded as adjustments to compensation expense. During the three months ended October 3, 2025, the Company recognized additional compensation expense of$7,005,000 as a result of changes in the market value of the trust assets with the same amount being recorded as gain in miscellaneous income (loss), net. During the three months ended September 27, 2024, the Company recognized a reduction in compensation expense of$7,157,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a loss in miscellaneous income (loss), net. During the nine months ended October 3, 2025, the Company recognized additional compensation expense of $14,632,000 as a result of changes in the market value of the trust assets with the same amount being recorded as income in miscellaneous income, net. During the nine months ended September 27, 2024, the Company recognized additional compensation expense of $14,299,000 as a result of changes in the market value of the trust assets with the same amount being recorded as income in miscellaneous income (loss), net.

Note 7: Supplemental Cash Flow Information

The following is supplemental disclosure of cash flow information:

Nine Months Ended
(In thousands) · October 3, 2025 · September 27, 2024
Cash paid during period:
Income taxes$32,367$29,060
Non-cash investing and financing activities:
Vested stock unit awards issued to settle accrued bonuses$12,179$10,846
Right-of-use asset obtained in exchange for operating lease obligations$3,540$56,714
Accrual for capital expenditures as of period end$653$537
Repurchases of common stock$617$-

-15 -

Note 8: Accounts Receivable, Net

At October 3, 2025 and January 3, 2025, accounts receivable, net, were comprised of the following:

October 3,January 3,
(In thousands)20252025
Billed accounts receivable$125,445$117,503
Unbilled accounts receivable64,17650,045
Allowance for contract losses and doubtful accounts(7,625)(6,141)
Total accounts receivable, net$181,996$161,407

The Company maintains allowances for estimated losses over the remaining contractual life of its receivables resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company’s ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer creditworthiness, current economic conditions, aging of amounts due and future expectations.

A reconciliation of the beginning and ending amount of the allowance for contract losses and doubtful accounts is as follows:

(In thousands)
Balance at January 3, 2025$6,141
Provision for contract losses and doubtful accounts2,097
Write-offs(613)
Balance at October 3, 2025$7,625

Note 9: Segment Reporting

The Company hastwo reportable operating segments based on two primary areas of service. The Engineering and other scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and health segment provides services in the areas of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments, but does not review total assets in evaluating segment performance and capital allocation.

Segment information for the three and nine months ended October 3, 2025 and September 27, 2024 follows:

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering and Other Scientific$124,016$115,244$367,130$355,193
Environmental and Health23,10421,03567,45966,555
Total revenues$147,120$136,279$434,589$421,748

Compensation and related expenses

-16 -

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering and Other Scientific$58,040$53,197$172,202$167,734
Environmental and Health12,01711,27136,20535,628
Total segment compensation and related expenses70,05764,468208,407203,362
Corporate compensation and related expenses17,66917,48652,69648,385
Total compensation and related expenses$87,726$81,954$261,103$251,747
Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering and Other Scientific$45,829$40,292$133,883$132,687
Environmental and Health8,4297,54724,14723,042
Total segment operating income54,25847,839158,030155,729
Corporate operating expense(25,220)(21,992)(67,383)(63,425)
Total operating income$29,038$25,847$90,647$92,304

Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include costs associated with its human resources, legal, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with its deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in its allowance for contract losses and doubtful accounts.

Capital Expenditures

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering and Other Scientific$691$887$1,472$1,769
Environmental and Health17-11874
Total segment capital expenditures7088871,5901,843
Corporate capital expenditures2,4311,3395,1912,899
Total capital expenditures$3,139$2,226$6,781$4,742

Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information.

-17 -

Depreciation and Amortization

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Engineering and Other Scientific$1,844$1,735$5,506$5,128
Environmental and Health5250148154
Total segment depreciation and amortization1,8961,7855,6545,282
Corporate depreciation and amortization6366041,8901,917
Total depreciation and amortization$2,532$2,389$7,544$7,199

No single client comprised more than 10%of the Company’s revenues during the three and nine months ended October 3, 2025 and September 27, 2024.

Note 10: Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of October 3, 2025.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statements of cash flows.

The Company leases office, laboratory, and storage space in 13 states and the District of Columbia, as well as in China, Hong Kong, Singapore, Switzerland, and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging betweenone andten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain.

The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the State of Arizona under an agreement that expires in January of 2043 that includes anoption to renew forone fifteen-year period.

The Company’s equipment leases are included in the ROU asset and liability balances, but are not material.

The Company leases excess space in its Silicon Valley and Natick facilities. Rental income of $226,000 and $742,000 was included in other income, net, for the three months ended October 3, 2025 and September 27, 2024, respectively. Rental income of $702,000 and $2,511,000 was included in other income, net, for the nine months ended October 3, 2025 and September 27, 2024, respectively.

-18 -

The components of lease expense included in other operating expenses on the condensed consolidated statements of income were as follows:

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Operating lease cost$3,091$3,251$9,199$7,758
Variable lease cost3773521,0931,100
Short-term lease cost4343781,1711,028

Supplemental cash flow information related to operating leases was as follows:

Three Months EndedNine Months Ended
(In thousands)October 3, 2025September 27, 2024October 3, 2025September 27, 2024
Cash paid for amounts included in the measurement of operating lease liabilities$1,868$1,654$6,149$6,002

Supplemental balance sheet information related to operating leases was as follows:

October 3, 2025September 27, 2024
Weighted Average Remaining Lease Term13.1 years14.0 years
Weighted Average Discount Rate6.3%6.2%

Maturities of operating lease liabilities as of October 3, 2025:

Operating
(In thousands)Leases
2025 (excluding the nine months ended October 3, 2025)$1,873
20269,109
20277,872
202810,594
20299,604
Thereafter89,229
Total lease payments128,281
Less imputed interest(45,683)
Total lease liability$82,598

Note 11: Contingencies

The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.

-19 -

Note 12: Subsequent Events

On October 30, 2025, the Company announced that its Board Directors approved a cash dividend of $0.30 per share of the Company’s common stock, payable December 19, 2025, to stockholders of record as of December 5, 2025.

On October 30, 2025, the Company announced that its Board of Directors authorized $100 million for the repurchase of the Company's common stock which amount is in addition to the amounts remaining under prior repurchase authorizations. These repurchase authorizations have no expiration date.

-20 -

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.